BCL2 Inhibitors Drugs Market, By Product (Combination therapy and Monotherapy), By Indication type (Follicular lymphoma, Chronic lymphocytic leukemia, DLBCL, Mantle cell leukemia and Others), By End-User, (Hospital, Ambulatory surgical centers and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI471721 | Publish Date: August 2023 | No. of Pages: 192

Global BCL2 Inhibitors Drugs Market Overview

BCL-2, also known as B Cell Lymphoma 2, is a B cell lymphoma gene that codes for a protein. This protein is thought to be an outer mitochondrial protein membrane that serves as a signaling mechanism for controlling mitochondrial permeability in response to apoptotic stimuli. In several organs, abnormal chromosome expression and translocation are considered cancer signs. The BCL-2 family consists of 25 apoptotic and anti-apoptotic members that keep the balance between new cell formation and old cell death. Venetoclax is the sole and only FDA-approved BCL-2 inhibitor for patients with chronic lymphocytic lymphoma (CLL). Various clinical trials for the development of novel BCL-2 inhibitors are currently underway. The BCL2 inhibitors drug market accounted for US$ 2.6 billion in 2020 and is estimated to be US$ 63.7 billion by 2030 and is anticipated to register a CAGR of 38.1%.

Global BCL2 Inhibitors Drugs Market Dynamics

Global BCL2 Inhibitors Drugs Market

Rising initiatives by government bodies

To lower mortality and morbidity rates, governments in both rich and developing countries are launching public awareness initiatives. This is expected to increase demand for cancer treatments that are effective. For example, in the United Kingdom, Public Health England, an executive department of the Department of Health, launched the “Be Clear on Cancer” campaign to improve early cancer diagnosis by organising a public awareness programme. The National Cancer Institute (NCI), a Federal Government institution, received US$ 5.2 billion in April 2016 for cancer research and training. In comparison to the previous year, the budget increased by 5.3 percent. The National Cancer Institute (NCI) conducts clinical trials on cancer patients who require repeated diagnosis to determine their prognosis.

Growth in business operations by emerging and small sized players

BCL2 inhibitors are emerging as a novel therapeutic agent for cancer management, with a large share of the future cancer therapy market projected. Due to the great diversity in the inhibitory mechanism, the BCL2 targeting strategy can create many options and pathways for pharmaceutical, biotechnological, and life science businesses, as proteins and genes in the BCL2 family are over-expressed in several malignancies. Following the success of the first commercially available BCL2 inhibitor medicine, it is envisaged that BCL2 inhibitors would change current cancer treatment tactics, with the approval of other products in this category boosting the overall cancer market. BCL2 inhibitors are also predicted to emerge as a novel component of combinational therapy in the future.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global BCL2 Inhibitors Drugs Market Segmentation

 


                                                          Global BCL2 Inhibitors Drugs Market

 

The global BCL2 inhibitor drug market is segmented based on product, Indication Therapy, End-User and region.

On the basis of Product, the global BCL2 inhibitor drugs market is segmented into Combination therapy and Monotherapy. Based on Indication type, the target market is segmented into Follicular lymphoma, Chronic lymphocytic leukemia, DLBCL, Mantle cell leukemia and Others. On the basis of End-User, the target market is segmented into Hospital, Ambulatory surgical centers and Others.

Regional Insights:

                                                                 Global BCL2 Inhibitors Drugs Market

On region the global BCL2 inhibitor drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to lead the global BCL-2 Inhibitor market, owing to rising cases of CLL and hematology malignancies patient pool. Furthermore, Venetoclax's approval in the region, as well as its combination with other medications, is expected to drive the market in the region. Ongoing strategic alliances are also expected to promote the growth of the BCL-2 inhibitors market in North America.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Report Scope:

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2030

Market representation

Revenue in USD Million & CAGR from 2020 – 2030

Market Segmentation

By Product- Combination therapy and Monotherapy

By Indication therapy–Follicular lymphoma, Chronic lymphocytic leukemia, DLBCL, Mantle cell leukemia and Other

By End-user– Hospital, Ambulatory surgical centers and others.

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the global BCL2 inhibitor drugs market report based on product, indication type, end user and region.

                                                                      Global BCL2 Inhibitors Drugs Market

Global BCL2 Inhibitor Drugs Market, By Region:

      • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Global BCL2 Inhibitors Drugs Market Key Players

Global BCL2 Inhibitors Drugs Market

The key players operating in the global BCL2 inhibitor drugs market includes F. Hoffmann-La Roche Ltd., AbbVie Inc. Novartis, AstraZeneca, Ascentage Pharma, BBeiGene, Ligand Pharma, and Tocris Bioscience. Leading pharmaceutical companies such as Roche Novartis, Amgen, AbbVie, and others are collaborating to create innovative BCL2 inhibitors, and more collaborations are planned in the near future to help speed up the drug development process.

Global BCL2 Inhibitors Drugs Market Company Profile

  • AbbVie Inc.*
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • F. Hoffmann-La Roche Ltd.
  • Novartis
  • AstraZeneca
  • Ascentage Pharma
  • BBeiGene
  • Ligand Pharma
  • Tocris Bioscience.

 “*” marked represents similar segmentation in other categories in the respective section

Global BCL2 Inhibitors Drugs Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for BCL2 Inhibitor Drugs Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Product
      • Market Snippet, By Indication type
      • Market Snippet, By End-User
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Global BCL2 Inhibitor Drugs Market, By Product, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Combination therapy
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Monotherapy
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  6. Global BCL2 Inhibitor Drugs Market, By Indication type, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Follicular lymphoma
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Chronic lymphocytic leukemia
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • DLBCL
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Mantle cell lymphoma
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030

 

  1. Global BCL2 Inhibitor Drugs Market, By End-User, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Hospital
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Ambulatory surgical centers
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030

 

  1. Global BCL2 Inhibitor Drugs Market, By Region, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Product, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Indication type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Product, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Indication type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Product, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Indication type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Product, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Indication type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Product, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Indication type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  2. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  3. Company Profiles
  • AbbVie Inc.*
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • F. Hoffmann-La Roche Ltd.
  • Novartis
  • AstraZeneca
  • Ascentage Pharma
  • BBeiGene
  • Ligand Pharma
  • Tocris Bioscience.

The Last Word

    • Future Impact
    • About Us
    • Contact

FAQs

The global BCL2 inhibitor drugs market is segmented based on product, indication type, end-user and region.

To lower mortality and morbidity rates, governments in both rich and developing countries are launching public awareness initiatives. This is expected to increase demand of global BCL2 inhibitor drugs market.

North America is expected to lead the global BCL-2 Inhibitor drugs market, owing to rising cases of CLL and hematology malignancies patient pool. Europe, Asia-Pacific, Latin America a d Middle-East & Africa are some of the another region considered in the report.

Leading pharmaceutical companies such as Roche Novartis, Amgen, AbbVie, and others are collaborating to create innovative BCL2 inhibitors, and more collaborations are planned in the near future to help speed up the drug development process.